

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/tau-24-96">https://dx.doi.org/10.21037/tau-24-96</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	
3	What data in particular will be shared?	The PSA data and safety data will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	1 year within the publication date, since the PSA data may be updated over time due to more data will be collected.
7	To whom will you share the data?	Urologists and prostate cancer surgeons who are interested in studies of darolutamide.
8	For what type of analysis or purpose?	For analysis to evaluate the safety of darolutamide in mHSPC patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: liujiabdy@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.